Background: Kaposiform hemangioendothelioma is a rare, intermediate, malignant tumor. The tumor's etiology remains unknown and there are no specific treatments. oBjective: In this study, we performed exome sequencing using DNA from a Kaposiform hemangioendothelioma patient, and found putative candidates for the responsible mutations. Method: The genomic DNA for exome sequencing was obtained from the tumor tissue and matched normal tissue from the same individual. Exome sequencing was performed on HiSeq2000 sequencer platform. results: Among oncogenes, germline missense single nucleotide variants were observed in the TP53 and APC genes in both the tumor and normal tissue. As tumor-specific somatic mutations, we identified 81 candidate genes, including 4 nonsense changes, 68 missense changes and 9 insertions/deletions. The mutations in ITGB2, IL-32 and DIDO1 were included in them. conclusion: This is a pilot study, and future analysis with more patients is needed to clarify: the detailed pathogenesis of this tumor, the novel diagnostic methods by detecting specific mutations, and the new therapeutic strategies targeting the mutation.
INTRODUCTION
According The disease concept of KHE was first proposed by Zukerberg in 1993. 1 The intermediate malignant tumor is a rare, locally aggressive, vascular tumor that usually occurs during childhood.
KHE may be associated with Kasabach-Merritt syndrome (KMS), a severe condition characterized by profound thrombocytopenia and hemorrhage. Because its mortality has been reported as 24%, it is necessary to clarify this tumor's detailed pathogenesis to develop early diagnostic methods and new therapeutic strategies. and lymphatic markers (D2-40, Prox1 or LYVE-1). Nevertheless, these cells were negative for GLUT-1 (infantile hemangioma marker) and HHV-8 (Kaposi's sarcoma marker).
No treatment guidelines exist for KHE. Previous reports have indicated that complete surgical excision is the most reliable treatment. 3 When surgical excision is impossible, combined therapy, including high-dose steroids, cytotoxic agent (vincristine or interferon-α) and cyclophosphamide, is required. Furthermore, a small number of studies have reported the effects of sirolimus, β-blocker, radiotherapy and embolization. 4, 5 However, the tumor is basically resistant to such treatments and complete remission is usually difficult to achieve.
Recently, advances in sequencing methods have enabled the identification of driver genes in many cancers. For example, mutations in BRAF are found in malignant melanoma, and BRAF inhibitors have already been utilized as novel treatments. Nonetheless, no studies exist on the causative genes in KHE. In this study, we performed exome sequencing of KHE and found putative candidates for the responsible mutations.
METHOD

Case
A 2-year-old Japanese boy visited our hospital to treat eruptions. His parents had noticed erythemas on his lower abdominal area at birth. His eruption was monitored at another hospital but the lesion gradually became larger, violaceous and painful.
On physical examination at the first visit, multiple, Based on the above findings, a diagnosis of KHE was made.
Since the tumor was limited to the lower abdomen without muscle infiltration or distant metastasis, and because the patient was not accompanied with KMS, the decision was taken to treat the tumor by serial excision. Three times resection removes almost all the lesions and the pain disappears.
DNA purification
The genomic DNA for exome sequencing was obtained Table 2 ). In addition, PTRF, OLFML2A, WDR81, or DIDO1 were detected as stop/gain SNVs (Table 3 ). Eight out of the 9 insertions/deletions did not cause frameshift and only G insertion in the IL-32 gene resulted in frameshift (Table 4) . Hetero  3  3  DDX18  chr02  118572361  A  C  Hetero  3  3  IL22RA1  chr01  24469556  G  T  Hetero  2  2  MAD1L1  chr07  2108930  G  T  Hetero  2  2  MRGPRE  chr11  3249491  A  C  Hetero  2  2  OBSCN  chr01  228400288  G  T  Hetero  2  2  SNED1  chr02  241974126  G  T  Hetero  2  2  ARSH  chrX  2936675  T  G  Hetero  5  8  CACNA1I  chr22  40045803  G  T  Hetero  1  2  LRFN4  chr11  66627620  G  T  Hetero  1  2  MRC2  chr17  60767030  C  A  Hetero  1  2  SHROOM2  chrX  9862832  G  T  Hetero  1  2  LAG3  chr12  6884651  A  C  Hetero  3  7  OBSL1  chr02  220422281  C  T  Hetero  1  3  TTN  chr02  179419226  A  C  Hetero  1  3  USP49  chr06  41774685  C  G  Hetero  1  3  GPRIN2  chr10  46999604  A  G  Hetero  2  12  ADAMTS7  chr15  79058378  A  G  Homo  1  8  FAM83E  chr19  49116421  G  T  Homo  0  2  LILRB3  chr19 of the tumor remain unknown. This is the first study to investigate mutations using the exome sequence, and we described several putative causing mutations of KHE.
For instance, the putative germline mutation seen in both tumor tissue and matched normal tissue was TP53 rs1042522. Given that TP53-deficient mice developed several spontaneous tumors including angiosarcoma, another malignant vascular tumor, TP53 mutation may play a role in the tumorigenesis of vascular tumors. 8 However, since this SNV is seen in about 60% of the population, there is a possibility that "second-hit" somatic mutation is also necessary for tumorigenesis. Another vascular anomaly, mucocutaneous venous malformation is caused by the combination of germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 and the somatic 'second hit' lesion-restricted mutation of TIE2. 9 Similarly, we previously indicated germline heterozygous SNV in KDR and TEM8 as the risk mutations for infantile hemangioma. 10 As infantile hemangioma typically appears on the head or face around the second week of life, the hypothesis proposed is that the clonal expansion of endothelial cells within the lesions may be a consequence of somatic events such as microvessel trauma during delivery.
We also identified 81 genes as candidates for somatic mutation. For example, ITGB2 has been strongly implicated in angiogenesis, suggesting the possible association with the pathogenesis of KHE. IL-32, which possesses heterozygous frameshift in KHE tissue, has also been known as a angiogenesis-related cytokine.
11,12
Furthermore, we found 4 nonsense mutations only in tumor tissue, including the DIDO1 gene, which is up-regulated by apoptotic signals and encodes a cytoplasmic protein that translocates to the nucleus upon apoptotic signal activation. DIDO1 is considered a tumor suppressor gene in myeloid cells, and thought to be significantly involved in the pathogenesis of myelodysplastic syndrome, a malignant blood disorder. 13 Accordingly, the DIDO1 gene may also be involved in the tumorigenesis of KHE.
CONCLUSION
These mutations have not been reported so far, which is consistent as driver mutations of the rare tumor. Potentially, multiple genetic abnormalities -rather than a single abnormality -may be involved in KHE. For instance, germline TP53 SNV and the somatic DIDO1 gene change may cooperate to induce tumorigenesis.
As limitations to this study, 'germline' mutation of TP53 may be due to the contamination of normal tissue and tumor tissue, because the parent DNA is not determined. In addition, the result of exome analysis was not confirmed by the sanger method. Since KHE is a rare tumor, the team was unable to collect other samples. This is a pilot study, and future analysis with more patients is need- 
